No revenue or guidance to trade on. The stock will move on binary PDUFA events (Sept 18 for zidesamtinib) and ASCO data presentations (May 29-June 2). Monitor for any FDA advisory committee announcements or clinical hold signals ahead of the PDUFA date.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · May 7 $102.40entry
- T+1 · 6mo ago +2.81%α +1.98% · $105.28
- T+5 · 6mo ago +2.75%α +1.25% · $105.22
- T+20 · 6mo ago −11.93%α −15.07% · $90.18
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nuvalent reported Q1 2026 results with a net loss of $109.3M ($1.39/share), wider than the $84.6M loss in Q1 2025, as R&D spending increased to $83.6M. The clinical-stage biotech reiterated key PDUFA milestones (zidesamtinib September 18, 2026) and submitted its NDA for neladalkib, but with no revenue and rising operating expenses, the quarter itself was a routine cash-burn update with no fundamental catalyst.
Key Facts
- Net loss of $109.3M for Q1 2026, vs $84.6M in Q1 2025
- Cash, cash equivalents and marketable securities of $1.3B as of March 31, 2026, down from $1.4B at year-end 2025
- R&D expenses of $83.6M in Q1 2026, up from $74.4M in Q1 2025
- G&A expenses of $35.8M in Q1 2026, up from $20.4M in Q1 2025
- NDA for neladalkib in TKI pre-treated ALK-positive NSCLC submitted to FDA
- Zidesamtinib NDA under FDA review with PDUFA target action date of September 18, 2026
- Cash runway anticipated into 2029
- Leadership promotions: Benjamin Lane to Chief Technology Operations Officer, Kirsten Duncan to VP Medical Affairs
Financial Impact
Net loss widened by $24.7M YoY to $109.3M; cash burn of ~$84.5M in Q1 2026 (from $1.37B to $1.29B)
Risk Factors
- FDA non-approval or delay for zidesamtinib (PDUFA Sept 18, 2026)
- Neladalkib NDA could face regulatory setbacks or require additional trials
- Cash burn rate increasing as commercial infrastructure is built pre-revenue
- Clinical trial enrollment or data readout risks for ALKAZAR and HEROEX-1
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001861560-26-000020 |
| Document: nuvl-20260507.htm | 0001861560-26-000020 |
| Document: 0001861560-26-000020-index-headers.html | 0001861560-26-000020 |
| Document: 0001861560-26-000020-index.html | 0001861560-26-000020 |
| Document: 0001861560-26-000020.txt | 0001861560-26-000020 |
| 8-K Data (Synthetic) | 0001861560-26-000020 |
Track record
18 reports on NUVL
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 8 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Viewing Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers